title: Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?
abstract: Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can be improved by incorporating measurements of serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding-protein 3 (IGFBP-3), and if these measurements might also identify men at higher risk.
authors.forename: A
authors.initials: A
authors.lastname: Wolk
authors.forename: S O
authors.initials: SO
authors.lastname: Andersson
authors.forename: C S
authors.initials: CS
authors.lastname: Mantzoros
authors.forename: D
authors.initials: D
authors.lastname: Trichopoulos
authors.forename: H O
authors.initials: HO
authors.lastname: Adami
mesh_terms: D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D012680:Sensitivity and Specificity
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D017430:Prostate-Specific Antigen